Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The landmark series: desmoid.Ann Surg Oncol. 2021; 28: 1682-1689
- An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).Ann Oncol. 2017; 28: 2399-2408
- Extra-abdominal desmoid tumor fibromatosis: a multicenter EMSOS study.BMC Cancer. 2021; 21: 437
Board. WCoTE. Soft tissue and bone tumours. 5th edition ed. Lyon2020.
- Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.Ann Surg. 2014; 259: 973-978
- Approach to screening for familial adenomatous polyposis (FAP) in a cohort of 226 patients with desmoid-type fibromatosis (DF): experience of a specialist center in the UK.Fam Cancer. 2021; 1: 69-74
- Treatment of desmoid tumors in 2019.JAMA Oncol. 2019; 5: 567-568
- Desmoid tumors: to treat or not to treat, that is the question.Cancer. 2020; 126: 5213-5221
- The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients.Eur J Cancer. 2020; 127: 96-107
- Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis).J Clin Oncol. 2017; 35: 1561-1569
- Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.Genes Chromosomes Cancer. 2015; 54: 606-615
- Desmoid tumors complicating familial adenomatous polyposis: a meta-analysis mutation spectrum of affected individuals.BMC Gastroenterol. 2015; 15: 84
- The prognostic role of β-catenin mutations in desmoid-type fibromatosis undergoing resection only: a meta-analysis of individual patient data.Ann Surg. 2021; 273: 1094-1101
- CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.PLoS One. 2014; 9e96391
- Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib: translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01).Ann Surg Oncol. 2016; 23: 1924-1927
- Differentially methylated regions in desmoid-type fibromatosis: a comparison between CTNNB1 S45F and T41A tumors.Front Oncol. 2020; 10: 565031
- PARP-1 expression as a prognostic factor in desmoid-type fibromatosis.Ann Diagn Pathol. 2020; 44: 151442
- A prospective observational study of active surveillance in primary desmoid fibromatosis.Clin Cancer Res. 2022; (clincanres.4205)https://doi.org/10.1158/1078-0432.CCR-21-4205
- Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought.Ann Surg Oncol. 2013; 20: 4096-4102
- Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.Ann Surg Oncol. 2009; 16: 2587-2593
- Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group.Eur J Cancer. 2017; 83: 125-131
- Event-free survival in desmoid-type fibromatosis (DTF): a pre-post comparison of upfront surgery versus wait-and-see approach.Eur J Surg Oncol. 2021; 47: 1196-1200
- Quality of life of patients with desmoid-type fibromatosis (QUALIFIED) [updated April 2, 2021 August 31, 2021]. ClinicalTrials.gov Identifier: NCT04289077].(Available at:)
- Active surveillance in desmoid-type fibromatosis: a systematic literature review.Eur J Cancer. 2020; 137: 18-29
- Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients.Eur J Cancer. 2015; 51: 186-192
- Desmoid tumours in the surveillance era: what are the remaining indications for surgery?.Eur J Surg Oncol. 2020; 46: 1310-1314
- Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series.J Clin Med. 2020; 9
- Functional analysis of young patients with desmoid-type fibromatosis: Initial surveillance does not jeopardize long term quality of life.Eur J Surg Oncol. 2020; 46: 1294-1300
- Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.J Clin Oncol. 2003; 21: 1390-1397
- A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.Ann Surg. 2013; 258: 347-353
Braggio DL, A.; Hernandez, L.; Mercier, K. A patient reported outcomes of treatments for desmoid tumors: an international natural history study. 2021 ASCO Annual Meeting.
- Desmoid type fibromatosis in patients.ESMO Virtual Congress. 2020;
- National clinical-biological prospective cohort of incident cases of aggressive fibromatosis (ALTITUDES) [updated May 13, 2021. ClinicalTrials.gov Identifier: NCT02867033].(Available at:)
- Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies.Cancer. 2020; 126: 3265-3273
- High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.Cancer. 2004; 100: 612-620
- Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.Pediatr Blood Cancer. 2013; 60: 1108-1112
- Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.Eur J Cancer. 2015; 51: 2800-2807
- Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.Fam Cancer. 2016; 15: 31-40
- Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.Cancer. 2001; 92: 1259-1264
- Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.J Clin Oncol. 2006; 24: 102-105
- Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).J Clin Oncol. 2006; 24: 1195-1203
- Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.Clin Cancer Res. 2010; 16: 4884-4891
- Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis.Cancer J. 2017; 23: 86-91
- Sorafenib for advanced and refractory desmoid tumors.N Engl J Med. 2018; 379: 2417-2428
- Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.Lancet Oncol. 2019; 20: 1263-1272
- Activity of sorafenib against desmoid tumor/deep fibromatosis.Clin Cancer Res. 2011; 17: 4082-4090
- Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).Eur J Cancer. 2017; 76: 60-67
- Pazopanib, a promising option for the treatment of aggressive fibromatosis.Anticancer Drugs. 2017; 28: 421-426
- The activity and safety of anlotinib for patients with extremity desmoid fibromatosis: a retrospective study in a single institution.Drug Des Devel Ther. 2020; 14: 3941-3950
- Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.J Cancer Res Clin Oncol. 2021; 147: 2127-2135
- Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: a phase II clinical trial.Cancer Sci. 2020; 111: 4187-4194
- Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis.ESMO Open. 2020; 5
- A timely oral option: single-agent vinorelbine in desmoid tumors.Oncologist. 2020; 25: e2013-e2016
- Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.Eur J Cancer. 2009; 45: 2930-2934
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).Ann Oncol. 2012; 23: 182-186
- Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.Jpn J Clin Oncol. 2020; 50: 1274-1281
- Notch inhibition in desmoids: "sure it works in practice, but does it work in theory?.Cancer. 2015; 121: 3933-3937
- A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.Clin Cancer Res. 2015; 21: 60-67
- Nirogacestat for adults with desmoid tumor/aggressive fibromatosis (DT/AF) (DeFi) [updated July 27, 2021August 31, 2021]. ClinicalTrials.gov Identifier: NCT03785964].(Available at:)
- A study of AL102 in patients with progressing desmoid tumors (RINGSIDE). 2021 (ClinicalTrials.gov Identifier: NCT04871282]. Available at:)
- Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998).Ann Oncol. 2013; 24: 2672-2676
- Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?.J Clin Oncol. 2010; 28: 2064-2069
- Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors.Cardiovasc Intervent Radiol. 2020; 43: 110-119
- Cryoablation of extra-abdominal desmoid tumors: a single-center experience with literature review.Diagnostics (Basel). 2020; 10
- CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment.Eur J Cancer. 2021; 143: 78-87
- The enigma of desmoid tumors.Ann Surg. 1999; 229: 866-872
- Toward observation as first-line management in abdominal desmoid tumors.Ann Surg Oncol. 2016; 23: 2212-2219
- Association of MRI T2 signal intensity with desmoid tumor progression during active observation: a retrospective cohort study.Ann Surg. 2020; 271: 748-755
- The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively.Eur Radiol. 2020; 30: 5768-5776
- Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis.Eur Radiol. 2020; 30: 895-902
- Progressive desmoid tumor: radiomics compared with conventional response criteria for predicting progression during systemic therapy-a multicenter study by the French Sarcoma Group.AJR Am J Roentgenol. 2020; 215: 1539-1548
- Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics.Eur J Radiol. 2020; 131: 109266
- PROMIS function scores are lower in patients who underwent more aggressive local treatment for desmoid tumors.Clin Orthop Relat Res. 2020; 478: 563-577
- Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis.Cancer. 2020; 126: 531-539
- (Available at:)
- (Available at:)
- Quality of life of patients with desmoid-type fibromatosis.(QUALIFIED) Available at:
Article info
Publication history
Published online: May 31, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
